Summary
An English court should not grant a declaration solely to influence a foreign court’s determination of an issue governed by that country’s law. Substantial harmonisation between the applicable foreign and domestic laws does not alter that principle.
The legitimate spin-off value of a judgment concerning UK rights must be distinguished from an advisory opinion sought for foreign proceedings. Comity, institutional competence and the avoidance of forum shopping require restraint where the parties have full access to the foreign court. A consequential effect on a UK supply chain does not supply the necessary domestic purpose.
Factual background
Teva sought an Arrow declaration that its proposed use of generic fingolimod would have been obvious at the priority date of Novartis’ European patent applications. After Novartis removed the UK designations, no relevant UK patent protection remained. The technical issue of obviousness was assumed in Teva’s favour for the preliminary discretionary trial.
Bacon J dismissed the claim in [2022] EWHC 2779 (Pat). She found no continuing uncertainty in the UK market and considered that the declaration’s remaining purposes were to assist Teva in resisting injunctions in Germany and another country through which its UK supplies passed.
The central issue on appeal was whether declaratory relief could properly be granted solely to influence foreign courts deciding questions under their own laws.
Held
Appeal dismissed unanimously. The judge was correct to refuse the Arrow declaration, although her approach had been more favourable to Teva than the governing principle permitted (per Arnold LJ, Nugee LJ and Sir Christopher Floyd agreeing).
The High Court’s power to grant declarations is discretionary. Ordinarily the court considers justice to each party, whether the declaration would serve a useful purpose and whether special reasons favour or oppose relief. An appellate court may interfere with that exercise only for an error of law or principle, consideration of an irrelevant factor, omission of a relevant factor or a plainly wrong conclusion.
It is wrong in principle for an English court to make a declaration solely to influence a foreign court’s decision on an issue governed by that foreign country’s law. The English courts do not provide advisory opinions on such questions and possess no special competence to decide them. Substantial harmonisation of the governing laws makes no difference. Comity requires restraint and the avoidance of jurisdictional imperialism and forum shopping. The court left open the possibility of a different position where a party lacked full and unimpeded access to the foreign court.
The legitimate spin-off value of a Patents Court judgment must be distinguished from a declaration sought solely for foreign use. A judgment deciding UK patent rights may properly assist settlement or persuade courts dealing with equivalent foreign designations. Likewise, an English court may decide foreign patent infringement where it substantively determines the dispute by applying foreign law. Neither situation justified Teva’s claim because no UK patent right or market uncertainty remained.
The possible effect of an injunction in another country on supplies to the UK was merely a consequential effect of that country applying its own law within its territory. It did not create a legitimate domestic purpose for the declaration. Novartis’ earlier application for a UK injunction and subsequent abandonment of UK protection also did not independently justify declaratory relief. Any consequences of that conduct were appropriately addressed through enforcement of cross-undertakings in damages and costs.
The court’s approach to earlier authorities
Available to signed-in members.
Appellate history
- Court of Appeal (Civil Division): The Court dismissed Teva’s appeal unanimously in [2022] EWCA Civ 1617 and upheld the refusal of declaratory relief.
- High Court, Patents Court: Bacon J dismissed Teva’s claim for an Arrow declaration in [2022] EWHC 2779 (Pat), finding no continuing uncertainty in the UK market and no sufficiently compelling justification for relief sought to influence foreign proceedings.
Appeal route
- Appealed from[2022] EWHC 2779 (Pat)This appealappeal dismissed unanimously
- This judgment [2022] EWCA Civ 1617 Court of Appeal (Civil Division)
Key cases cited
22 authorities cited.
- Mexichem UK Ltd v Honeywell International Inc [2020] EWCA Civ 473
- TQ Delta, LLC v Zyxel Communications UK Ltd & Anor [2019] EWCA Civ 1277
- Glaxo Group Ltd & Ors v Vectura Ltd [2018] EWCA Civ 1496
- Fujifilm Kyowa Kirin Biologics Co, Ltd v Abbvie Biotechnology Ltd & Anor [2017] EWCA Civ 1
- IPcom GmbH & Co Kg v HTC Europe Co Ltd & Ors [2013] EWCA Civ 1496
- Glaxo Group Ltd v Genentech Inc & Anor [2008] EWCA Civ 23
- Nokia Corporation v Interdigital Technology Corporation [2006] EWCA Civ 1618
- Messier-Dowty Ltd v Sabena SA [2000] 1 WLR 2040
- Lisa Dräxlmaier GmbH v BOS GmbH & Co KG [2022] EWHC 2823 (Pat)
- Takeda UK Ltd v F Hoffmann-La Roche AG (Rev 1) [2019] EWHC 1911 (Pat)
- Pfizer Ltd v F. Hoffmann-La Roche AG & Anor [2019] EWHC 1520 (Pat)
- Takeda UK Ltd v F. Hoffmann-La Roche AG [2018] EWHC 2155 (Ch)
- Deutsche Bank (China) Co Ltd, Shanghai Branch v Bright Food Hong Kong Ltd [2017] EWHC 3543 (Comm)
- Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd (Rev 1) [2017] EWHC 395 (Pat)
- Actavis Group HF v Eli Lilly & Company [2012] EWHC 3316 (Pat)
- Fresenius Kabi Deutschland GmbH v Carefusion 303 Inc [2011] EWHC 2959 (Pat)
- TNS Group Holdings Ltd. v Nielsen Media Research Inc [2009] EWHC 1160 (Pat)
- Arrow Generics Ltd & Anor v Merck & Co, Inc [2007] EWHC 1900 (Pat)
- Financial Services Authority v Rourke [2002] CP Rep 14
- Cairnstores Ltd v Aktiebolaget Hässle [2002] FSR 35
- Gillette Safety Razor Co v Anglo-American Trading Co Ltd (1913) 30 RPC 465
- Roll-Forming Machine Xa ZB 10/09
Sign in to see how the court treated each authority. A free account is enough.
Cases citing this case
8 later cases · 5 positive · 1 neutral · 2 caution
Most senior citing decisions:
- Tesla Inc & Anor v InterDigital Patent Holdings, Inc & Ors [2025] EWCA Civ 193 considered
- Lenovo Group Limited & Ors v Telefonaktiebolaget LM Ericsson & Anor [2025] EWCA Civ 182 applied
- Alcatel Lucent SAS v Amazon Digital UK Limited & Ors [2025] EWCA Civ 43 applied
- Panasonic Holdings Corporation v Xiaomi Technology UK Limited & Ors [2024] EWCA Civ 1143
- Lenovo Group Limited & Ors v Ericsson Limited & Anor [2024] EWHC 2941 (Pat)
- Panasonic Holdings Corporation v Xiaomi Technology UK Limited & Ors [2024] EWHC 1733 (Pat)
- JP Morgan International Finance Limited v WEREALIZE.COM Limited [2024] EWHC 1437 (Comm)
- Lenovo Group Limited & Ors v Interdigital Technology Corporation & Ors [2024] EWHC 596 (Ch)
Sign in for the full treatment table. A free account is enough.